Evidence map›Paper›PMID 36432736›Full record

ReviewPharmaceutics2022

Truong Giang Luu, Hee-Kwon Kim

Open access · goldAbstract readReview
In one paragraph

Review in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 27 citations in OpenAlex.

  1. Influence of Translocator Protein (Life (Basel, Switzerland) · 2026
    Article
  2. Comparative Study of [Molecular imaging and biology · 2025
    Article
  3. Targeting mitophagy in neurodegenerative diseases.Nature reviews. Drug discovery · 2025
    Review
  4. Observational
  5. Review
  6. Advances and Challenges in Depression Marker Research.Neuropsychiatric disease and treatment · 2025
    Review
  7. Recent Progress in Synthesis ofNuclear medicine and molecular imaging · 2024
    Review
  8. Article
  9. Review
  10. Review
  11. Recent Advances ofInternational journal of molecular sciences · 2023
    Review
  12. Synthesis, In Silico and In Vitro Characterization of NovelPharmaceuticals (Basel, Switzerland) · 2023
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Truong Giang LuuDepartment of Nuclear Medicine, Molecular Imaging & Therapeutic Medicine Research Center, Jeonbuk National University Medical School and Hospital, Jeonju 54907, Republic of Korea.
Hee-Kwon KimDepartment of Nuclear Medicine, Molecular Imaging & Therapeutic Medicine Research Center, Jeonbuk National University Medical School and Hospital, Jeonju 54907, Republic of Korea.ORCID 0000-0001-7612-7049
Jeonbuk National University · KRJeonbuk National University Hospital · KR

Funding

National Research Foundation of Korea NRF-2021R1A2C1011204
6 · The paper itself

Abstract

Translocator protein 18 kDa (TSPO) is a transmembrane protein in the mitochondrial membrane, which has been identified as a peripheral benzodiazepine receptor. TSPO is generally present at high concentrations in steroid-producing cells and plays an important role in steroid synthesis, apoptosis, and cell proliferation. In the central nervous system, TSPO expression is relatively modest under normal physiological circumstances. However, some pathological disorders can lead to changes in TSPO expression. Overexpression of TSPO is associated with several diseases, such as neurodegenerative diseases, neuroinflammation, brain injury, and cancers. TSPO has therefore become an effective biomarker of related diseases. Positron emission tomography (PET), a non-invasive molecular imaging technique used for the clinical diagnosis of numerous diseases, can detect diseases related to TSPO expression. Several radiolabeled TSPO ligands have been developed for PET. In this review, we describe recent advances in the development of TSPO ligands, and

Indexed as

molecular imagingneuroinflammationPETtranslocator proteinTSPO ligands

Identifiers

PMID36432736
PMCPMC9697781
OpenAlexW4309542830

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.